×
S&P 500   3,785.38
DOW   30,775.43
QQQ   280.28
S&P 500   3,785.38
DOW   30,775.43
QQQ   280.28
S&P 500   3,785.38
DOW   30,775.43
QQQ   280.28
S&P 500   3,785.38
DOW   30,775.43
QQQ   280.28
NASDAQ:KALV

KalVista Pharmaceuticals Stock Forecast, Price & News

$9.84
+0.16 (+1.65%)
(As of 06/30/2022 12:00 AM ET)
Add
Compare
Today's Range
$9.29
$9.92
50-Day Range
$8.16
$13.61
52-Week Range
$8.00
$24.80
Volume
99,939 shs
Average Volume
268,694 shs
Market Capitalization
$241.50 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$47.00
30 days | 90 days | 365 days | Advanced Chart

Receive KALV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for KalVista Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

KALV Stock Forecast (MarketRank)

Overall MarketRank

1.81 out of 5 stars

Medical Sector

795th out of 1,433 stocks

Pharmaceutical Preparations Industry

385th out of 684 stocks

Analyst Opinion: 3.5Community Rank: 4.9Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -
KalVista Pharmaceuticals logo

About KalVista Pharmaceuticals (NASDAQ:KALV)

KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include KVD001, a plasma kallikrein inhibitor that completed a Phase II clinical trial for the treatment of DME; KVD900, which has completed Phase II clinical trial for an oral on-demand therapy for acute HAE attacks; and KVD824, an oral product candidate for the treatment of HAE. The company is headquartered in Cambridge, Massachusetts.

KALV Stock News Headlines

KalVista Pharmaceuticals Announces Non-...
KalVista Pharmaceuticals: Q3 Earnings Insights
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:KALV
Employees
70
Year Founded
N/A

Company Calendar

Last Earnings
12/09/2021
Today
7/01/2022
Next Earnings (Estimated)
7/12/2022
Fiscal Year End
4/30/2023

Price Target and Rating

Average Stock Price Forecast
$47.00
High Stock Price Forecast
$51.00
Low Stock Price Forecast
$42.00
Forecasted Upside/Downside
+377.6%
Consensus Rating
Buy
Rating Score (0-4)
3
Research Coverage
4 Analysts

Profitability

Net Income
$-46.24 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$12.69 million
Book Value
$10.53 per share

Miscellaneous

Free Float
22,972,000
Market Cap
$241.50 million
Optionable
Not Optionable
Beta
1.82














KalVista Pharmaceuticals Frequently Asked Questions

Should I buy or sell KalVista Pharmaceuticals stock right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for KalVista Pharmaceuticals in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" KalVista Pharmaceuticals stock.
View analyst ratings for KalVista Pharmaceuticals
or view top-rated stocks.

What is KalVista Pharmaceuticals' stock price forecast for 2022?

4 brokerages have issued twelve-month target prices for KalVista Pharmaceuticals' shares. Their KALV stock forecasts range from $42.00 to $51.00. On average, they expect KalVista Pharmaceuticals' stock price to reach $47.00 in the next year. This suggests a possible upside of 377.6% from the stock's current price.
View analysts' price targets for KalVista Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

How has KalVista Pharmaceuticals' stock price performed in 2022?

KalVista Pharmaceuticals' stock was trading at $13.23 at the beginning of 2022. Since then, KALV stock has decreased by 25.6% and is now trading at $9.84.
View the best growth stocks for 2022 here
.

When is KalVista Pharmaceuticals' next earnings date?

KalVista Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, July 12th 2022.
View our earnings forecast for KalVista Pharmaceuticals
.

How were KalVista Pharmaceuticals' earnings last quarter?

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) released its quarterly earnings results on Thursday, December, 9th. The specialty pharmaceutical company reported ($0.80) EPS for the quarter, missing analysts' consensus estimates of ($0.79) by $0.01.
View KalVista Pharmaceuticals' earnings history
.

Who are KalVista Pharmaceuticals' key executives?

KalVista Pharmaceuticals' management team includes the following people:
  • Mr. Thomas Andrew Crockett M.B.A., CEO & Director (Age 47, Pay $1.03M)
  • Mr. Benjamin L. Palleiko, Chief Bus. Officer & CFO (Age 56, Pay $711.85k)
  • Dr. Christopher M. Yea Ph.D., Chief Devel. Officer (Age 58, Pay $697.34k)
  • Dr. Edward P. Feener Ph.D., Chief Scientific Officer (Age 62)
  • Jarrod Aldom, VP of Corp. Communications
  • Ms. Rachel Morten, Head of Regulatory Affairs and QA
  • Dr. Michael D. Smith Pharm.D., Sr. VP of Devel. (Age 43)
  • Dr. Paul K. Audhya M.B.A., M.D., Chief Medical Officer
  • Mr. Stephen Donnelly, Director of Fin. and Company Sec.
  • Mr. John B. McKune, VP of Fin. (Age 46)

What other stocks do shareholders of KalVista Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other KalVista Pharmaceuticals investors own include Heron Therapeutics (HRTX), Sorrento Therapeutics (SRNE), Cara Therapeutics (CARA), SCYNEXIS (SCYX), TG Therapeutics (TGTX), VBI Vaccines (VBIV), Aldeyra Therapeutics (ALDX), Catalyst Pharmaceuticals (CPRX), Corbus Pharmaceuticals (CRBP) and Pfizer (PFE).

What is KalVista Pharmaceuticals' stock symbol?

KalVista Pharmaceuticals trades on the NASDAQ under the ticker symbol "KALV."

How do I buy shares of KalVista Pharmaceuticals?

Shares of KALV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is KalVista Pharmaceuticals' stock price today?

One share of KALV stock can currently be purchased for approximately $9.84.

How much money does KalVista Pharmaceuticals make?

KalVista Pharmaceuticals (NASDAQ:KALV) has a market capitalization of $241.50 million and generates $12.69 million in revenue each year. The specialty pharmaceutical company earns $-46.24 million in net income (profit) each year or ($3.030010) on an earnings per share basis.

How many employees does KalVista Pharmaceuticals have?

KalVista Pharmaceuticals employs 70 workers across the globe.

How can I contact KalVista Pharmaceuticals?

KalVista Pharmaceuticals' mailing address is 55 Cambridge Parkway Suite 901E, CAMBRIDGE MA, 02142. The official website for KalVista Pharmaceuticals is www.kalvista.com. The specialty pharmaceutical company can be reached via phone at 857-999-0075, via email at [email protected], or via fax at 866-553-3269.

This page (NASDAQ:KALV) was last updated on 7/1/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.